On December 16, 2022, a decision of the National Union of Health Insurance Funds (UNCAM) relating to the update of the NABM Nomenclature for IVD tests was published in the Official Journal of the French Republic. Various changes were introduced, including the inclusion of new codes, modifications of the existing ones, and tariff changes.
Among the newly-introduced seven codes, there are the following:
- 0032 “Control cytopathological examination of cervical smear for organized screening” with a tariff of €14.85;
- 0033 “Liquid-phase control cytopathological examination [single-layer technique] of cervical smear for organized screening” with a tariff of €14.85;
- 0034 “Immunocytochemical examination of cervical smear or tissue with 1-2 antibodies, without signal quantification for individual screening” with a tariff of €48.06;
- 0035 “Immunocytochemical examination of cervical smear or tissue with 1-2 antibodies, without signal quantification for organized screening” with a tariff of €48.06.
See the details in French here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).